2012
Newer drugs and earlier treatment
Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, Ajana F, Melliez H, Paltiel AD, Freedberg KA, Yazdanpanah Y. Newer drugs and earlier treatment. AIDS 2012, 26: 45-56. PMID: 22008655, PMCID: PMC3237010, DOI: 10.1097/qad.0b013e32834dce6e.Peer-Reviewed Original ResearchConceptsCD4 cell countAntiretroviral therapyHIV RNACD4 cellsHIV diseaseCells/Life expectancyCell countMean CD4 cell countMean age 38 yearsAge 38 yearsMedical resource utilizationLifetime costsUndiscounted life expectancyCost of careAIDS Complications (CEPAC) modelART initiationHIV CostRegimen costsAntiretroviral drugsART costsEarly treatmentCopies/High-income countriesEfficacious drugs
2009
When to start antiretroviral therapy in resource-limited settings.
Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E. When to start antiretroviral therapy in resource-limited settings. Annals Of Internal Medicine 2009, 151: 157-66. PMID: 19620143, PMCID: PMC3092478, DOI: 10.7326/0003-4819-151-3-200908040-00138.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsAnti-Infective AgentsCD4 Lymphocyte CountCohort StudiesComputer SimulationCost-Benefit AnalysisDecision TreesDisease ProgressionDrug Administration ScheduleHealth Care CostsHIV InfectionsHumansLife ExpectancySensitivity and SpecificitySouth AfricaTrimethoprim, Sulfamethoxazole Drug CombinationConceptsAntiretroviral therapyCD4 countLong-term survivalCells/LART initiationCells/L.ART initiation strategiesIncremental cost-effectiveness ratioSevere opportunistic diseaseDoris Duke Charitable FoundationLife expectancyCD4 count thresholdHIV treatment decisionsCost-effectiveness ratioInternational clinical trialsBase-case analysisResource-limited settingsYears of lifeCost-effectiveness analysisPerson's life expectancyObservational cohortCD4 thresholdHIV diseaseTreatment guidelinesEarly therapy
2002
Prevention of Human Immunodeficiency Virus—Related Opportunistic Infections in France: A Cost-Effectiveness Analysis
Yazdanpanah Y, Goldie S, Paltiel A, Losina E, Coudeville L, Weinstein M, Gerard Y, Kimmel A, Zhang H, Salamon R, Mouton Y, Freedberg K. Prevention of Human Immunodeficiency Virus—Related Opportunistic Infections in France: A Cost-Effectiveness Analysis. Clinical Infectious Diseases 2002, 36: 86-96. PMID: 12491207, DOI: 10.1086/344902.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAntiretroviral Therapy, Highly ActiveChemopreventionCost-Benefit AnalysisFranceGuidelines as TopicHIV InfectionsHumansLife ExpectancyQuality of LifeConceptsCost-effectiveness ratioTMP-SMZAntiretroviral therapyHIV diseaseOpportunistic infectionsHuman immunodeficiency virus (HIV) diseaseMycobacterium avium complex bacteremiaIncremental cost-effectiveness ratioPerson lifetime costsActive antiretroviral therapyEra of HAARTPneumocystis carinii pneumoniaHuman immunodeficiency virusQuality-adjusted life expectancyCost-effectiveness analysisOral ganciclovirCytomegalovirus infectionToxoplasmic encephalitisCarinii pneumoniaImmunodeficiency virusTherapeutic optionsClinical impactFrench patientsProphylaxisInfectionProphylaxis for Human Immunodeficiency Virus–Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines
Goldie SJ, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR, Craven DE, Kimmel AD, Zhang H, Cohen CJ, Freedberg KA. Prophylaxis for Human Immunodeficiency Virus–Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines. JAMA Internal Medicine 2002, 162: 921-928. PMID: 11966344, DOI: 10.1001/archinte.162.8.921.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-Infective AgentsAntiprotozoal AgentsAtovaquoneCD4 Lymphocyte CountCost-Benefit AnalysisDapsoneDrug CostsHumansLife ExpectancyModels, TheoreticalNaphthoquinonesPentamidinePneumonia, PneumocystisPractice Guidelines as TopicQuality-Adjusted Life YearsConceptsQuality-adjusted life yearsCD4 cell countQuality-adjusted life expectancyPneumocystis carinii pneumoniaCD4 cell count increasePCP prophylaxisCell count increaseCell countCarinii pneumoniaClinical guidelinesCD4 cell count criteriaInitial CD4 cell countCD4 lymphocyte countPrimary PCP prophylaxisActive antiretroviral therapyCohort of HIVHuman immunodeficiency virusTMP/SMXCount increaseAntiretroviral therapyLymphocyte countHIV infectionImmunodeficiency virusTrimethoprim-sulfamethoxazoleProphylaxis
2001
Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts
Yazdanpanah Y, Chêne G, Losina E, Goldie S, Merchadou L, Alfandari S, Seage G, Sullivan L, Marimoutou C, Paltiel A, Salamon R, Mouton Y, Freedberg K. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. International Journal Of Epidemiology 2001, 30: 864-871. PMID: 11511618, DOI: 10.1093/ije/30.4.864.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsCD4 Lymphocyte CountChi-Square DistributionCohort StudiesFemaleFranceHumansIncidenceMaleMiddle AgedRisk FactorsStatistics, NonparametricConceptsPneumocystis carinii pneumoniaPrimary opportunistic infectionCommon opportunistic infectionOpportunistic infectionsCarinii pneumoniaToxoplasmic encephalitisCytomegalovirus infectionIncidence rateGroupe d'Epidémiologie Clinique du SIDAAIDS Reference CenterCD4 lymphocyte declineIncidence of HIVHuman immunodeficiency virusAbsence of prophylaxisHIV risk behaviorsHigh incidence rateHospital-based information systemCandida esophagitisCount declineImmunodeficiency virusLymphocyte declineAntiretroviral drugsClinical guidelinesSpecific infectionsClinical cohortThe Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease
Freedberg K, Losina E, Weinstein M, Paltiel A, Cohen C, Seage G, Craven D, Zhang H, Kimmel A, Goldie S. The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease. New England Journal Of Medicine 2001, 344: 824-831. PMID: 11248160, DOI: 10.1056/nejm200103153441108.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountComputer SimulationCost-Benefit AnalysisDirect Service CostsDisease ProgressionDrug CostsDrug Therapy, CombinationHealth Care CostsHIV InfectionsHumansLife ExpectancyModels, BiologicalQuality-Adjusted Life YearsRNA, ViralUnited StatesValue of LifeConceptsQuality-adjusted yearThree-drug therapyCombination antiretroviral therapyCD4 cell countQuality of lifeAntiretroviral therapyHIV diseaseClinical benefitDrug costsLife expectancyCell countInitial CD4 cell countThree-drug antiretroviral regimensHuman immunodeficiency virus (HIV) infectionHIV RNA levelsPerson lifetime costsImmunodeficiency virus infectionMajor clinical trialsDirect medical costsStandard of careProgression of diseaseLifetime direct medical costsCost-effectiveness ratioServices Utilization SurveyCost effectivenessPreevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus
Paltiel A, Goldie S, Losina E, Weinstein M, Seage G, Kimmel A, Zhang H, Freedberg K. Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus. Clinical Infectious Diseases 2001, 32: 783-793. PMID: 11229847, DOI: 10.1086/319223.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAntiviral AgentsChemopreventionCost-Benefit AnalysisCytomegalovirusCytomegalovirus InfectionsGanciclovirHIV InfectionsHumansModels, BiologicalPolymerase Chain ReactionPredictive Value of TestsQuality-Adjusted Life YearsSensitivity and SpecificityValganciclovirConceptsHuman immunodeficiency virusDuration of survivalPreemptive therapyCMV casesImmunodeficiency virusCMV polymerase chain reactionEnd-stage HIV diseaseUpcoming trialsCMV preemptive therapySalvage antiretroviral therapyCells/microLClinical trial dataCMV prophylaxisAntiretroviral therapyHIV diseaseComplication rateEfficacy assumptionsPolymerase chain reactionDisease progressionClinical uncertaintyDrug effectsPatientsTrial dataTherapyChain reaction
1999
The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS.
Scharfstein JA, Paltiel AD, Weinstein MC, Seage GR, Losina E, Craven DE, Freedberg KA. The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS. International Journal Of Technology Assessment In Health Care 1999, 15: 531-47. PMID: 10874380, DOI: 10.1017/s026646239901538x.Peer-Reviewed Original Research
1998
Cost Effectiveness of Prophylaxis for Opportunistic Infections in AIDS
Freedberg K, Paltiel A. Cost Effectiveness of Prophylaxis for Opportunistic Infections in AIDS. PharmacoEconomics 1998, 14: 165-173. PMID: 10186457, DOI: 10.2165/00019053-199814020-00005.Peer-Reviewed Original ResearchConceptsHIV patient careOpportunistic infectionsInfection preventionPatient careImmune system destructionSpecific opportunistic infectionsMajor opportunistic infectionNew antiretroviral therapiesQuality of lifeCost-effectiveness evaluationCost-effectiveness analysisCost effectivenessProphylaxis regimensAntiretroviral therapyHIV diseaseHIV infectionViral loadClinical guidelinesConsiderable financial strainProphylaxisClinical advancesViral replicationEffective agentInfectionHIVA Monte Carlo Simulation of Advanced HIV Disease
Paltiel AD, Scharfstein JA, Seage GR, Losina E, Goldie SJ, Weinstein MC, Craven DE, Freedberg KA. A Monte Carlo Simulation of Advanced HIV Disease. Medical Decision Making 1998, 18: s93-s105. PMID: 9566470, DOI: 10.1177/0272989x98018002s11.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioMonte Carlo simulation frameworkDecision makersCost-effectiveness ratioQuality-adjusted monthsPrice assumptionsNet costLife yearsData estimatesCost-effective usePatient care resourcesState transition modelCare resourcesMakersAdvanced HIV diseaseSensitivity analysisLate-stage diseaseBaseline resultsAlternative interventionsQuality of lifeTreatment of AIDSCostCMV prophylaxisGanciclovir prophylaxisThe Cost-effectiveness of Preventing AIDS-Related Opportunistic Infections
Freedberg KA, Scharfstein JA, Seage GR, Losina E, Weinstein MC, Craven DE, Paltiel AD. The Cost-effectiveness of Preventing AIDS-Related Opportunistic Infections. JAMA 1998, 279: 130-136. PMID: 9440663, DOI: 10.1001/jama.279.2.130.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic InfectionsAnti-Infective AgentsCD4 Lymphocyte CountChemopreventionCost-Benefit AnalysisCytomegalovirus InfectionsData CollectionHealth Care CostsHumansLife ExpectancyMarkov ChainsModels, TheoreticalMycobacterium avium-intracellulare InfectionMycosesPneumonia, PneumocystisQuality-Adjusted Life YearsRisk FactorsToxoplasmosisUnited StatesConceptsPneumocystis carinii pneumoniaCD4 cell countQuality-adjusted life expectancyOpportunistic infectionsCell countLife expectancyAdvanced human immunodeficiency virus diseaseAverage total lifetime costsHuman immunodeficiency virus (HIV) diseaseMycobacterium avium complex infectionMulticenter AIDS Cohort StudyIncremental cost-effectiveness ratioHIV patient careCost of prophylaxisCost-effective prophylaxisDirect medical costsAIDS Cohort StudyLifetime direct medical costsLong-term survivalCost-effectiveness ratioServices Utilization SurveyMarkov simulation modelTotal lifetime costsCytomegalovirus diseasePreventing AIDS
1997
The Cost-Effectiveness of Fluconazole Prophylaxis against Primary Systemic Fungal Infections in AIDS Patients
Scharfstein JA, Paltiel AD, Freedberg KA. The Cost-Effectiveness of Fluconazole Prophylaxis against Primary Systemic Fungal Infections in AIDS Patients. Medical Decision Making 1997, 17: 373-381. PMID: 9343795, DOI: 10.1177/0272989x9701700402.Peer-Reviewed Original Research